AstraZeneca, Daiichi's breast cancer drug gets broader U.S. approval
By Reuters Staff 2 Min Read FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth (Reuters) - AstraZeneca and Daiichi Sankyo’s breast cancer drug has been approved as a treatment for a certain type of advanced gastric cancer in the United States, the British drugmaker said on Monday. Drugmakers are using biomarker-driven drugs to treat patients with rare tumours. AstraZeneca made a $7-billion bet on the treatment, Enhertu, when it partnered with Daiichi in 2019 in a direct challenge to Roche. The treatment has now b...